Title:
B-1A LYMPHOCYTE AND/OR MACROPHAGE TARGETING AND ACTIVATION TO TREAT MEDICAL CONDITIONS WITH INFLAMMATORY OR AUTOIMMUNE COMPONENTS
Document Type and Number:
WIPO Patent Application WO/2017/087868
Kind Code:
A3
Abstract:
Methods and formulations to target and activate B-1a lymphocytes and/or macrophages are described. The methods and formulations can be delivered to the respiratory tract to target B-1a lymphocytes and/or macrophages in the pleural cavity. Conditions with inflammatory or autoimmune components can be treated. B-1a lymphocytes and/or macrophages can be targeted and activated using fibrils or fibril-forming peptides.
Inventors:
STEINMAN LAWRENCE (US)
KURNELLAS MICHAEL (US)
ROTHBARD JONATHAN (US)
KURNELLAS MICHAEL (US)
ROTHBARD JONATHAN (US)
Application Number:
PCT/US2016/062878
Publication Date:
July 13, 2017
Filing Date:
November 18, 2016
Export Citation:
Assignee:
UNIV LELAND STANFORD JUNIOR (US)
International Classes:
A61K38/08; A61P37/06; A61K35/62; B32B5/16
Foreign References:
| US20070053844A1 | 2007-03-08 | |||
| US20120328703A1 | 2012-12-27 | |||
| US20090325931A1 | 2009-12-31 |
Other References:
KURNELLAS, MP ET AL.: "Amyloid Fibrils Composed of Hexameric Peptides Attenuate Neuroinflammation", SCIENCE TRANSLATIONAL MEDICINE, vol. 5, no. 179, 3 April 2013 (2013-04-03), pages 179ra42, XP055335468
Attorney, Agent or Firm:
WINGER, C. Rachal (US)
Download PDF: